Project Grant R01AI191323
Award Date 9/18/25
Completion Date 8/31/30
Dollars Obligated $147K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Mali
Similar Awards
- This Project Grant award of $1,553,810 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate a genomic surveillance approach for monitoring artemisinin resistance in Plasmodium falciparum malaria in Africa. The project aims to identify genetic mutations and altered biological functions associated with artemisinin resistance, which is a critical concern as resistance emerges...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $808,919 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Trustees of Boston University. The 5-year grant, which began on September 18, 2025, aims to develop novel aglain derivatives as host-targeted antivirals against dengue virus (DENV) and other mosquito-borne arboviruses. The research program seeks to optimize the aglain chemical series and study their modulation of the host...
- The University of Notre Dame DU Lac received a $147,486 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The objective of this grant is to develop and parameterize a temperature-dependent, trait-based transmission model for dengue virus (DENV) transmission by the Aedes aegypti mosquito, incorporating the impacts of insecticides such as the larvicide temephos and the...
- This federal Project Grant award of $294,583, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel cost-effective multispecific antibody therapeutic product for dengue by Mapp Biopharmaceutical, Inc. The goal is to create a therapeutic that combines the efficacy of two broadly neutralizing antibodies into a single half-life extended molecule, enabling higher...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $549,032 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Griffith University in Australia. The objective of this 3-year grant, with a performance period from September 2025 to August 2028, is to develop a safe and effective multistage malaria vaccine using Griffith University's biopolymer particle-based vaccine platform technology. The proposed research aims to design...
- This $423,500 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to examine the role of invariant natural killer T (iNKT) cells in driving pathogenic T cell responses in experimental cerebral malaria. The research aims to determine how the T cell receptor (TCR) mechanosensing properties of iNKT cells shape the development of CD8 T cell-mediated pathology in Plasmodium infection. The grant...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $423,125 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Texas A&M University System Health Science Center. The grant, awarded on July 17, 2025, aims to develop an intein-based QF2 system for controllable protein expression in the nervous system of the Aedes aegypti mosquito. This research seeks to leverage genetic and synthetic biology tools to disrupt the propagation of...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,808 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis, Missouri. The funding will support research to identify heme-binding proteins in the malaria parasite Plasmodium falciparum and investigate their role in maintaining heme homeostasis. The project aims to better understand how the parasite detoxifies heme, an essential but redox-active...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $267,168 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Institut Pasteur DU Cambodge, a non-profit research establishment in Phnom Penh, Cambodia. The grant aims to leverage access to Plasmodium vivax (P. vivax) parasite diversity to identify culture-adaptable strains and develop robust in vitro culture systems. This would enable advanced studies on P. vivax malaria, which poses...
- This federal Project Grant award of $649,530.00, awarded on July 7, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of B cell receptor (BCR)-dependent infection as a mechanism of immune-mediated enhancement of Dengue virus (DENV) infection and pathogenesis. The funded research aims to explore how cross-reactive non-neutralizing antibodies, when expressed...